FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 叮噹健康科技集團有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | | | 本月底結存 | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500 ...

Group 1 - The core viewpoint of the articles highlights Dingtang Health's strategic focus on expanding its innovative drug portfolio through partnerships and new product launches, particularly in the oncology sector [1][2] - Dingtang Health has launched the innovative anti-tumor drug, Lurasidone Hydrochloride Tablets, which received approval for market entry on May 29 of this year [1] - Since 2025, Dingtang Health has initiated the "New Specialty Drug. Life Ark Plan," introducing multiple innovative drugs to enhance patient accessibility and adherence [1] Group 2 - In the first half of 2025, Dingtang Health reported revenue of 2.327 billion yuan, reflecting a year-on-year growth of 2.6% [2] - The gross profit for the same period was 816 million yuan, with a gross margin of 35% [2] - The company incurred a loss of 52.02 million yuan, which represents a 42.1% reduction in losses compared to the same period in 2024 [2] - Adjusted net profit loss was 5.759 million yuan, showing a 78.2% improvement from the previous year [2]

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.ddjkjt.com and the HKEXnews website at www.hkexnews.hk in place of printed copies. You should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the"Intermediaries") and provide your email address to your Intermediaries. If you want to receive the Corporate Com ...

DINGDANG HEALTH TECHNOLOGY GROUP LTD. 叮噹健康科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) (Stock code 股份代號：9886) Dear registered shareholder(s), 26 September 2025 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 20 September 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", DINGDANG HEALTH TECHNOLOGY GROUP LTD. (the "Company") is writing to ...

DINGDANG HEALTH TECHNOLOGY GROUP LTD. 叮噹健康科技集團有限公司 （於開曼群島註冊成立的有限公司） 股份代號 : 09886 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 釋義 | 4 | | 管理層討論及分析 | 10 | | 公司管治及其他資料 | 21 | | 簡明綜合財務報表審閱報告 | 41 | | 簡明綜合損益及其他全面收益表 | 42 | | 簡明綜合財務狀況表 | 44 | | 簡明綜合權益變動表 | 46 | | 簡明綜合現金流量表 | 47 | | 簡明綜合財務報表附註 | 48 | 公司資料 姜山先生 （主席） 張守川先生 樊臻宏博士 提名委員會 楊文龍先生 （主席） 樊臻宏博士 張守川先生 姜山先生 （於2025年5月30日獲委任） 李楚衡女士 （於2025年5月30日獲委任） 董事會 執行董事 楊文龍先生 （主席兼總裁） 徐寧先生 俞雷先生 于慶龍先生 楊益斌先生 非執行董事 李楚衡女士 （於2025年5月30日獲委任） 蔡俐女士 （於2025年5月30日辭任） 獨立非執行董事 張守川先生 樊臻宏博士 姜山先生 ...

Group 1 - Dingtang Health has formed a significant partnership with Xiansheng Pharmaceutical to launch the insomnia medication Dali Leisheng on its O2O platform, providing a comprehensive service including instant retail, medication guidance, online health consultations, and health education [1] - Since February, Dingtang Health has collaborated with numerous original drug companies, establishing the "Original Drug Supply Alliance" to enhance its new drug O2O launch platform capabilities [1] - The company is also investing in smart pharmacy construction, upgrading its "Xingyuan System" to support its smart pharmacies across four major regions in China [1] Group 2 - For the first half of 2025, Dingtang Health reported revenues of 2.327 billion yuan, a year-on-year increase of 2.6%, with a gross profit of 816 million yuan and a gross margin of 35% [2] - The company incurred a loss of 52.02 million yuan during this period, which is a 42.1% reduction compared to the same period in 2024, while the adjusted net loss was 5.759 million yuan, narrowing by 78.2% year-on-year [2] Group 3 - On September 23, Dingtang Health's stock price surged over 15% to close at 0.9 HKD per share, with a trading volume of 6.5591 million HKD [4]

Group 1: Collaboration and Services - Dingdang Health has formed a significant partnership with Xiansheng Pharmaceutical to launch the insomnia medication Daridorexant (brand name: Kewike) on its O2O platform, providing more medication options for those suffering from sleep disorders [1] - The collaboration aims to offer a comprehensive service that includes instant retail of medications, medication guidance, online health consultations, and health education [1] - Since February, Dingdang Health has partnered with numerous original research pharmaceutical companies to establish the "Original Drug Supply Alliance," enhancing its platform for the launch of new drugs [1] Group 2: Market Potential and Product Approval - The insomnia medication market in China shows significant potential, with nearly half (48.5%) of adults experiencing sleep issues, which increase with age, primarily manifesting as difficulty falling asleep, waking during the night, and early waking [1] - On June 20, Xiansheng Pharmaceutical's insomnia medication (generic name: Daridorexant) was approved for market launch, having previously received approvals in 11 countries including the US, UK, Switzerland, Japan, Canada, and Hong Kong [1] - The introduction of this product on Dingdang Health's platform is expected to provide more effective and safer treatment options for China's large population of insomnia sufferers [1]

每经AI快讯，9月12日，叮当健康(09886.HK)涨超5%，截至发稿，涨6.82%，报0.94港元，成交额524.07 万港元。 （文章来源：每日经济新闻） ...

Group 1 - Dingdang Health (09886) saw a stock price increase of over 5%, reaching a rise of 6.82% to HKD 0.94, with a trading volume of HKD 5.2407 million [1] - Recently, Dingdang Health announced a partnership with Eli Lilly, expanding the availability of Tirzepatide injection (Mounjaro) to pharmacies in Guangzhou and Shenzhen, following its introduction in Beijing [1] - According to Tianfeng Securities, over 2.6 billion people globally were affected by overweight/obesity in 2020, indicating a growing weight loss market, with Eli Lilly being a leading company in this sector [1] Group 2 - Dingdang Health aims to leverage Eli Lilly's innovative drug products and health education capabilities, combined with its own extensive smart pharmacy network, end-to-end intelligent logistics system, and professional healthcare team, to provide a comprehensive health solution for overweight/obese and diabetic populations [1] - The collaboration is expected to enhance medication accessibility and health management levels for targeted demographics [1]

叮当健康表示，依托礼来卓越的创新药产品、专业的健康科普能力，以及叮当健康广泛的多功能智慧药 房网络、端到端智能仓配体系、专业医生药师服务团队、全生命周期健康管理体系，双方将共同为超 重/肥胖、糖尿病等人群带来一站式健康解决方案，提升用药可及性和健康管理水平。 消息面上，近日，叮当健康宣布与利来集团达成合作，继北京地区之后，叮当健康在广州、深圳的药房 正式上架替尔泊肽注射液(穆峰达)。天风证券研报称，2020年全球已有超过26亿人受到超重/肥胖影响， 减重市场持续扩容，礼来是减重领域的龙头企业之一。 智通财经APP获悉，叮当健康(09886)涨超5%，截至发稿，涨6.82%，报0.94港元，成交额524.07万港 元。 ...